Track topics on Twitter Track topics that are important to you
Bona Vida, Inc. www.bonavida.com (“Bona Vida” or the “Company”) is excited to announce the launch of its global CBD platform, focused on developing a portfolio of brand and product verticals within the animal and adult health and wellness space. The Company will be exclusively focused on CBD derived from industrial hemp, with the goal of becoming the dominant worldwide player in this high growth industry.
“We are at the beginning of a fundamental shift in the global acceptance of CBD as a lifestyle improvement product and with the passing of the Hemp Farming Act within the 2018 Farm Bill recently, we see exciting new market opportunities opening for CBD-based wellness products across the board,” said Damian Dalla-Longa, CEO of Bona Vida. “We believe that positive regulatory tailwinds will continue to enhance market access for consumers and that industrial hemp is quickly becoming an agricultural commodity with almost limitless product alternatives.
“Bona Vida strives to be the market leader in all of these verticals by deploying a contract manufacturing and distribution model that currently does not exist in the space. This will provide Bona Vida with a first-mover competitive advantage, help scale the business quickly and deliver maximum value to our shareholders,” said Dalla-Longa.
Bona Vida is also simultaneously launching a research and development initiative, designed to implement dosing studies and clinical trials across its entire product offering. “As the industry continues to mature, having causal evidence that substantiates the impact Bona Vida's products have on customer well-being will help us stand out in the marketplace,” said Dalla-Longa. “Product education is effectively non-existent in the industry today and we are going to be at the forefront of changing consumer perception that includes educational tools and compassionate one-on-one consultations geared towards informing customers on the benefits of CBD products.”
Bona Vida recently closed its second capital raise, led by Navy Capital, and is pleased to announce the appointment of Sean Stiefel to the Board of Directors. "We are excited about what Bona Vida is doing in the CBD space, and are looking forward to supporting the company as the sector evolves," said Stiefel. “Adult and animal health and wellness should be a very high growth vertical for years to come.”
About Bona Vida:
Bona Vida is the leading developer of a portfolio of brand and product verticals within the animal and adult health and wellness space and plans to become the preeminent player in the global hemp-derived CBD industry. Importantly, Bona Vida will only be sourcing CBD from industrial hemp. Bona Vida is developing and operating in the global hemp-derived CBD space with a focus on the following markets: Pets (dogs and cats), Veterinary, Livestock and human health and wellness. For more information, please visit: www.bonavida.com. Bona Vida can be reached at: firstname.lastname@example.org.
About Navy Capital:
Navy Capital's research-oriented fundamentally driven investment process focuses on identifying attractive opportunities within the legal hemp and cannabis space. Navy Capital seeks to find best in class businesses within key verticals of the industry. Those verticals include Consumer, Healthcare, Technology, Industrials and Agriculture.
What We Look For
Navy Capital invests in select public and private companies that will gain market share over time in their respective verticals. Businesses that have recurring revenue and management teams that have a large share of their net worth in the company and are deeply passionate about their culture and customers are most attractive to us. For more information, visit navycapital.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company’s production capabilities, expectations concerning the receipt of all necessary approvals from applicable state departments of agriculture or other state and federal regulatory bodies, and the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving hemp, cannabinoids, and cannabis generally; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; interpretations of federal and state laws and regulations by applicable regulatory and governmental bodies; the hemp industry in the United States generally; income tax and regulatory matters; the ability of the Company to implement its business strategies; competition; the success of farming activities and production; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur, or that they will occur in the manner anticipated. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...
BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...